Overview of the CONVERT trial in LS-SCLC

Corinne Faivre-Finn, FRCR, MD, PhD of University of Manchester and the Christie NHS Foundation Trust, UK, gives an overview of the CONVERT trial (ISRCTN91927162), which is an international, randomized control study in patients, who have limited-stage small-cell lung cancer (LS-SCLC). The study compared two schedules of radiotherapy, which was delivered either twice a day or as a higher dose once a day, concurrently with chemotherapy. There was no difference in survival between the two groups, however, with lower toxicity levels and longer survival compared to previous clinical trials. CONVERT was not an equivalence trial, but Dr Faivre-Finn points out that once daily radiotherapy could be offered to patients in a routine practice, considering factors like patients travel limitations or radiotherapy departments not being able to provide radiotherapy twice a day. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.

Share this video